TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Recruitment Maneuvers in ARDS: Effects on Respiratory Function and Inflammatory Markers.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age over 18~* hospitalization in the ICU~* under mechanical ventilation~* Acute Lung Injury (ALI)criteria~* first week of ALI~* hemodynamic stability (mAP \> 75 mmHg since one hour)~* informed consent signed (patient or relatives)~Exclusion Criteria:~* pregnancy~* obesity (BMI \> 40 kg/M2)~* high probability of D-28 death~* severe burn injury~* severe hepatic cirrhosis (Child-Pugh C)~* aplasia~* HIV or CHV infection~* use of more than 0.5 mg/kg of steroïds~* immunosuppressor agents~* hemopathy~* contra indications for BAL~* contra indications for recruitment maneuvers~* baro-traumatism~* left cardiac failure~* chronic respiratory failure~* inclusion in another study during the past month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Team Approach to Polypharmacy Reduction to Improve Mobility Long-Term Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* residing in 2 long-term care facilities in Brampton, ON~* on 5 or more medications~* 70 years of age or older~* adequate English language

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAPERMD (Type: None): 80 Long term care residents on 5 or more medications aged over 70 from 2 long term care facilities

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ctDNA in Patients With Thyroid Nodules

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older;~* presence of one or more thyroid nodules who are going to have a fine needle aspiration biopsy performed as part of their normal care.~Exclusion Criteria:~* Prior history of cancer excluding basal cell carcinoma of the skin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Oculomotor and Spatial Cognition Deficits in Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion Criteria: Inclusion criteria for this study are (1) able and willing to give written informed consent; (2) no contraindications to MRI (cardiac pacemaker, aneurysm clip, cochlear implants, IUD, shrapnel, history of metal fragments in eyes, neurostimulators or other metal devices, weight of 250lbs or more, claustrophobia) and (3) medically stable. Sedation will not be used for MRI studies because cooperation is essential.~Exclusion Criteria:~* Any subject is excluded from the imaging studies if they have any contraindications to MRI such as cardiac pacemaker, aneurysm clip, cochlear implants, pregnancy in the later stages (because of body size and limited comfort for MRI studies), IUD, shrapnel, history of metal fragments in eyes, neurostimulators, weight of 250 lbs. or more, or claustrophobia. Individuals with mental retardation, neurologic disease or significant medical illness that might effect neuronal or vascular physiology will not be recruited.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Antipsychotic (Type: EXPERIMENTAL): Antipsychotic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A RCT to Compare the Effects of Two Wound Products on Biofilm Disruption in DFUs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient is able to understand the study and is willing to consent to the study.~2. The patient consents to the ongoing use of their de-identified photos by the Sponsor for purposes outside of this study.~3. The patient must be at least 18 years of age.~4. Males and females - provided they are not pregnant or lactating and if of reproductive age are using contraception.~5. The patient has presented with a DFU which, according to the clinical judgement of the Investigator, has a suspected biofilm~6. The patient has a DFU of Grade 1 or 2 according to the Meggit-Wagner scale. Grade 1 - Superficial ulcers limited to the dermis Grade 2 - Ulcers are transdermal with exposed bone or tendon, and without osteomyelitis or abscess formation~7. The patient's ulcer is suitable to be dressed with IODOSORB or SOLOSITE.~8. The patient has an ABPI \>0.49; or toe pressure \>50mmHg.~Exclusion Criteria:~1. Patients with a known history of poor compliance with medical treatment.~2. Patients who have participated in this study previously and who healed or were withdrawn.~3. Patients who are participating in any other clinical study.~4. Patients that have received continuous treatment with Iodosorb (on any wound) in the past 8 weeks (Iodosorb must not be continuously used for more 3 months) or whose reference ulcer has been treated with Iodosorb in the past 2 weeks.~5. Patients with a history of any thyroid disorders, e.g. Hashimoto's thyroiditis, Graves disease or non-toxic nodular goitre.~6. Patients undergoing treatment with mercurial antiseptics, taurolidine or lithium.~7. Patients with a known sensitivity to iodine or any of the other ingredients in IODOSORB, SOLOSITE or ALLEVYN Non-adhesive~8. Patients with severe renal impairment~9. Patients with an ulcer less than 3cm diameter.~10. Patients with an ulcer that is not exuding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Solosite gel (Type: PLACEBO_COMPARATOR): Hydrogel with preservatives, used to create a moist wound environment.
- Iodosorb (Type: ACTIVE_COMPARATOR): Cadexomer iodine gel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diabetes mellitus Type 2~2. Age \> 50 years~3. HbA1c \> 7%~4. Left ventricular diastolic dysfunction determined by echocardiography as average E/é ≥13 or average E/é≥8 and LA volume ≥34ml/m2~5. Stable anti-diabetic medication for the last 6 weeks which should include a maximal tolerated dose of metformin (unless contraindication or intolerance to metformin does exist).~6. Indication to increase anti-diabetic medication as judged by the investigator~7. Written informed consent prior to study participation~Exclusion Criteria:~1. Diabetes mellitus type 1~2. Echocardiography:~   * decreased left ventricular systolic function, ejection fraction (EF) \<45%~  * regional wall motion abnormalities~  * hypertrophic cardiomyopathy (septum \>15mm)~  * severe valvular dysfunction~3. Uncontrolled hypertension~4. Atrial fibrillation~5. Obstructive sleep apnea syndrome~6. Use of DPP-4 Inhibitor (Dipeptidyl-peptidase IV Inhibitor), GLP 1 agonists, Thiazolindinedione~7. Kidney disease CKD 4 and more (GFR \< 30 ml/min/1.73)~8. Liver disease (ALT or AST \> 3 times the upper limit of norm) or known liver cirrhosis~9. Active malignant disease~10. HbA1c \> 8.5%~11. Recent (\<3 months) clinically significant coronary or cerebral vascular event~12. Pregnant females as determined by positive \[serum or urine\] hCG test at Screening or prior to dosing. Participants of child-bearing age should use adequate contraception as defined in the study protocol.~13. Lactating females~14. The subject has a history of any other illness, which, in the opinion of the Investigator, might pose an unacceptable risk by administering study medication.~15. The subject received an investigational drug within 30 days prior to inclusion into this study~16. The subject has any current or past medical condition and/or required medication to treat a condition that could affect the evaluation of the study~17. The subject is unwilling or unable to follow the procedures outlined in the protocol~18. The subject is mentally or legally incapacitated

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Linagliptin (Type: ACTIVE_COMPARATOR): Linagliptin 5 mg (tablets) once daily for 6 month
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (tablets) once daily for 6 month

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed metastatic prostate cancer that is castrate-resistant.~* 2-3 lesions suitable for radiotherapy.~* ECOG Performance status 0-2.~  * Adequate bone marrow, hepatic and renal function~ * At least 4 weeks must have elapsed prior to commencement of idronoxil treatment since prior chemotherapy, investigational drug or biologic therapy~Exclusion Criteria:~* Chemotherapy regimens with delayed toxicity within the last 4 weeks.~* Any situation where the use of suppository therapy is contra-indicated or impractical(eg. chronic diarrhoea, colostomy, ulcerative colitis).~* No concurrent systemic chemotherapy or biologic therapy is allowed.~* Psychiatric disorder or social or geographic situation that would preclude study participation.~* Patient unable to provide consent

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 NOX66 400mg and SBRT (Type: EXPERIMENTAL): Group 1 patients will receive 400mg of Idronoxil (NOX66) suppository (1 suppository) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.
- Group 2 NOX66 800mg and SBRT (Type: EXPERIMENTAL): Group 2 patients will receive 800mg of Idronoxil (NOX66) suppository (2 suppositories) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma~* Measurable disease~* For non-secretors, measurable protein by Freelite or plasmacytoma~* Asymptomatic disease~Exclusion Criteria:~* POEMS syndrome~* Plasma cell leukemia~* Receiving steroids greater than the equivalent of 10 mg prednisone~* Infection not controlled by antibiotics~* HIV infection~* Known active hepatitis B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TBL 12 (Type: EXPERIMENTAL): TBL 12, sea cucumber, will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Dexmedetomidine and Remifentanil on Carotid Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consenting adult patients (age \>50 years) undergoing carotid endarterectomy with general anesthesia.~Exclusion Criteria:~* Receiving another alpha 2-adrenoreceptor agonist;~* Contraindication to dexmedetomidine, including allergy;~* Current hepatic disease (liver function tests \> twice upper limit of normal);~* Renal insufficiency, as defined by a creatinine \> 2.0 mg/dL;~* Mentally impairment, including dementia or delirium;~* Heart block ;~* Sick sinus syndrome;~* Atrial fibrillation with a low ventricular response (\< 50 bpm);~* Absolute or relative hypovolemia;~* Prior stroke;~* Severe left-ventricular dysfunction

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Remifentanil (Type: ACTIVE_COMPARATOR): Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
- Dexmedetomidine (Type: ACTIVE_COMPARATOR): Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CARES Lumbar Artificial Disc Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Treated with the lumbar TDR.~* Signed IRB approved consent document.~Key Exclusion Criteria:~* None known.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Sodium Bicarbonate in Generally Healthy People With Low Bicarbonate

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Estimated glomerular filtration rate (eGFR) ≥ 60 ml/min/1.73m2~* Urinary albumin/creatinine ratio \< 30 mg/gm~* Serum bicarbonate ≤ 23 mEq/L (average of the two most recent measurements within the past year)~* Age ≥ 50 years~Exclusion Criteria:~* Blood pressure ≥ 160/100 mm Hg~* Serum potassium \< 3.5 mEq/L~* New York Heart Association Class 3 or 4 heart failure symptoms~* Chronic oxygen therapy~* Chronic obstructive pulmonary disease requiring daily bronchodilator or prednisone therapy~* Weight ≥ 160 kg~* Use of sodium bicarbonate, sodium citrate, potassium citrate, or potassium bicarbonate within the previous two weeks.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sodium Bicarbonate (Type: EXPERIMENTAL): All participants will receive oral sodium bicarbonate for 6 weeks (On-treatment period). After the 6 week visit, participants will stop taking sodium bicarbonate and return for a final visit 4 weeks later (Off-treatment period).~The initial dose of sodium bicarbonate prescribed is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d. Half the dose will be taken by mouth in the morning and the other half in the evening.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non Invasive Evaluation of Bronchial Inflammation in Infants : a Study of the Sputum Cellularity After Hypertonic Saline Induction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 6 and 36 mo.~* Ambulatory or hospitalized.~* With %SaO2 ³ 95%~* Parents information and non-opposition from the parents~Exclusion Criteria:~* Any underlying chronic disease~* Been given oral corticosteroid during the last four weeks~* Known adverse events with nebulized saline solution~* With cold during the 4 last weeks for the controled group.~* With %SaO2 \< 95%

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 3 Years
- Healthy Volunteers: f

Study Arms:
- Acute exacerbation (Type: OTHER): Cell profiles Analysis after sputum induction in infants with Acute exacerbation
- Uncontrolled asthma (Type: OTHER): Cell profiles Analysis after sputum induction in infants with Uncontrolled asthma
- controlled asthma (Type: OTHER): Cell profiles Analysis after sputum induction in infants controlled asthma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or females from 40 to 80 years of age~* Diagnosis of IPF~* Honeycombing (fibrosis in the lung) on high-resolution computerised tomography (HRCT) scan of less than or equal to 5%~* Willing and able to have 2 right heart catheterizations performed~* Willing to have monthly lab tests to monitor liver function~* Able to perform the 6 minute walk test (indicated adequate physical function)~* Must have meet lung function requirements~* Normal liver function tests~* Negative serum pregnancy test~* Willing to use at least 2 reliable methods of contraception~* Able to understand and willing to sign informed consent form~Exclusion Criteria:~* No restrictive lung disease (other than usual interstitial pneumonia or IPF)~* No obstructive lung disease~* No recent or active respiratory exacerbations~* No recent hospitalization for an IPF exacerbation~* No recent history of alcohol abuse~* Chronic sildenafil (or same drug class) use for pulmonary hypertension~* Chronic treatment with certain medications for IPF within 30 days of randomization~* No other serious medical conditions

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ambrisentan (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic confirmation of AML or high risk MDS.~* Elderly cohort (70 years of age or more): no prior chemotherapy treatment for AML/high risk MDS and not currently candidates for intensive chemotherapy.~* Relapsed/refractory cohort (18 years of age or more): relapsed or refractory to prior treatment.~* ECOG performance status of 0 or 1.~* Total bilirubin \< 1.5 x upper limit of normal (ULN).~* AST/SGOT and ALT/SGPT \< 2.5 x ULN.~* Serum creatinine \< 1.5 x ULN.~* Patients must read, understand, and sign a written informed consent form (ICF).~* Women of childbearing potential and male patients' female partners must use an acceptable method of contraception while on study, and for 3 months after study drug treatment.~Exclusion Criteria:~* Pregnant or lactating women.~* Patients with uncontrolled, intercurrent illness, active or uncontrolled infections, or a fever \> 38.5C (not due to tumor fever) on the day of scheduled dosing.~* Patients with serious illnesses or medical conditions, including laboratory results, which, in the investigator's opinion, would interfere with a patient's participation, or with the interpretation of the results.~* Patients treated with an investigational drug within 30 days prior to study initiation.~* Known hypersensitivity to HDAC inhibitors or to any of the components of MG-0103.~* Known HIV or active hepatitis B or C.~* Any condition that may affect the patient's ability to sign the ICF and undergo study procedures.~* Any conditions that will put the patient at undue risk or discomfort as a result of adherence to study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): Elderly (≥65 years) untreated arm
- 2 (Type: EXPERIMENTAL): Relapsed/Refractory Arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy